Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

Recruiting now · Phase 4

Conditions studied: Autoimmune Diseases, Dry Eye, Neurotrophic Keratitis

In brief

Single-site, open label pilot study of 20 autoimmune patients diagnosed with dry eye demonstrating via the proparacaine challenge some peripheral corneal pain component. At least 16 patients will receive and complete 12 weeks of 80 units of Acthar Gel to be injected subcutaneously twice weekly via Acthar Gel single-dose pre-filled SelfJectTM injector (SelfJect) to assess the effects on subjective sensation of ocular pain, conjunctival and corneal staining, in vivo assessments of corneal nerves as measured by confocal imaging, VAS scales of common neuropathic pain symptoms and comfort of SelfJect will be assessed.

Key facts

Study ID

NCT06964269

Run by

Toyos Clinic

People needed

20

Starts

2025-02-11

Expected to finish

2028-02-28

Last updated by the study team

2025-05-11

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Subject can read, understand, sign and informed consent.
• Provision of signed and dated informed consent form and HIPPA authorization.
• Stated willingness to comply with all study procedures and availability
• for the duration of the study
• Male or female aged 18-85 years.
• Normal eyelid anatomy
• Patients diagnosed with dry eye for at least 6 months prior to enrollment.
• Patients with Symptom Bother score at Baseline of 50.6 or greater.
• Patients with a diagnosis of any autoimmune disease.
• Patients with one or more corneal neuroma as seen on baseline confocal microscopy.
• Patients with partial or total relief of corneal pain with one drop of proparacaine over 15 minutes post-instillation.
• No prior use of Acthar Gel SelfJect or otherwise for any indication.

You may not qualify if…

• 1. Have a known hypersensitivity or contraindication to the investigational product or their components.
• Unwilling to participate in study activities or report for study visits. 3. Current pregnancy or lactation per self-report. Patients who are unwilling to use an effective method of birth control while participating in the study and for four weeks after the last dose of study drug is administered.
• Use of antihistamines, mast cell stabilizers, or prescription eye drops within 24 hours prior to screening and for the study, unless the dose has been stable for 14 days.
• Current use of cenegermin, topical nerve growth factor or platelet rich plasma or use within the past 30 days.
• Treatment with another investigational drug or other intervention within 30 days of screening.
• Have serious or severe disease or uncontrolled medical condition that in the judgement of the investigator could confound study assessments, limit compliance, or pose safety risks.
• Systemic medications known to cause dry eye should not be used including antimuscarinics, antihistamines, vitamin A analogs, antianxiety agents, and others unless stable for at least 30 days.

Where it is running

• Toyos Clinic — Nashville, Tennessee, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.